Carregant...
SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
EMPA-REG OUTCOME and CANVAS trials were designed to study the cardiovascular safety of empagliflozin and canagliflozin, respectively. Both studies were sufficiently powered to study the non-inferiority for cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (DM) and showed superio...
Guardat en:
| Publicat a: | Diabetes Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Healthcare
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5688986/ https://ncbi.nlm.nih.gov/pubmed/29076040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-017-0320-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|